Influenza-like illnesses affect millions each year in the United States. Determining definitively the cause of symptoms is important for patient management. Our Precision experts Emily Boller, Research Scientist, Shawn Davies, Associate Director, Cynthia Miller, VP, Director, Access Experience Team, and Ivar Jensen, Vice President – HEOR Consulting, joined forces with Jordan Chase and Anne Beubrun to look at the data and develop a cost-consequence model demonstrating the clinico-economic impacts of implementing PCR testing with Xpert Xpress compared to current testing strategies. They found The Xpert Xpress CoV-2/Flu/RSV plus enables targeted reliable test results for patients with acute respiratory symptoms resulting in appropriate and efficient testing and treatment.
